The calcium-transporting ATPase ATP2A2, also known as SERCA2a, is a critical ATPase responsible for Ca 21 re-uptake during excitation-contraction coupling. Impaired Ca 21 uptake resulting from decreased expression and reduced activity of SERCA2a is a hallmark of heart failure 1 . Accordingly, restoration of SERCA2a expression by gene transfer has proved to be effective in improving cardiac function in heart-failure patients 2 , as well as in animal models 3 . The small ubiquitin-related modifier (SUMO) can be conjugated to lysine residues of target proteins 4 , and is involved in many cellular processes 5 . Here we show that SERCA2a is SUMOylated at lysines 480 and 585 and that this SUMOylation is essential for preserving SERCA2a ATPase activity and stability in mouse and human cells. The levels of SUMO1 and the SUMOylation of SERCA2a itself were greatly reduced in failing hearts. SUMO1 restitution by adeno-associated-virus-mediated gene delivery maintained the protein abundance of SERCA2a and markedly improved cardiac function in mice with heart failure. This effect was comparable to SERCA2A gene delivery. Moreover, SUMO1 overexpression in isolated cardiomyocytes augmented contractility and accelerated Ca 21 decay. Transgene-mediated SUMO1 overexpression rescued cardiac dysfunction induced by pressure overload concomitantly with increased SERCA2a function. By contrast, downregulation of SUMO1 using small hairpin RNA (shRNA) accelerated pressure-overload-induced deterioration of cardiac function and was accompanied by decreased SERCA2a function. However, knockdown of SERCA2a resulted in severe contractile dysfunction both in vitro and in vivo, which was not rescued by overexpression of SUMO1. Taken together, our data show that SUMOylation is a critical post-translational modification that regulates SERCA2a function, and provide a platform for the design of novel therapeutic strategies for heart failure.
The calcium-transporting ATPase ATP2A2, also known as SERCA2a, is a critical ATPase responsible for Ca 21 re-uptake during excitation-contraction coupling. Impaired Ca 21 uptake resulting from decreased expression and reduced activity of SERCA2a is a hallmark of heart failure 1 . Accordingly, restoration of SERCA2a expression by gene transfer has proved to be effective in improving cardiac function in heart-failure patients 2 , as well as in animal models 3 . The small ubiquitin-related modifier (SUMO) can be conjugated to lysine residues of target proteins 4 , and is involved in many cellular processes 5 . Here we show that SERCA2a is SUMOylated at lysines 480 and 585 and that this SUMOylation is essential for preserving SERCA2a ATPase activity and stability in mouse and human cells. The levels of SUMO1 and the SUMOylation of SERCA2a itself were greatly reduced in failing hearts. SUMO1 restitution by adeno-associated-virus-mediated gene delivery maintained the protein abundance of SERCA2a and markedly improved cardiac function in mice with heart failure. This effect was comparable to SERCA2A gene delivery. Moreover, SUMO1 overexpression in isolated cardiomyocytes augmented contractility and accelerated Ca 21 decay. Transgene-mediated SUMO1 overexpression rescued cardiac dysfunction induced by pressure overload concomitantly with increased SERCA2a function. By contrast, downregulation of SUMO1 using small hairpin RNA (shRNA) accelerated pressure-overload-induced deterioration of cardiac function and was accompanied by decreased SERCA2a function. However, knockdown of SERCA2a resulted in severe contractile dysfunction both in vitro and in vivo, which was not rescued by overexpression of SUMO1. Taken together, our data show that SUMOylation is a critical post-translational modification that regulates SERCA2a function, and provide a platform for the design of novel therapeutic strategies for heart failure.
It was previously reported that SERCA2a activity could be modulated by post-translational modifications (PTMs) such as glutathiolation 6 and nitration 7 . We identified SUMO1 as a SERCA2a interactor in a proteomic screen ( Supplementary Fig. 1a, b ). We confirmed that SERCA2a binds in vivo to SUMO1 and to ubiquitin-conjugating enzyme E2I (UBE2I, also known as UBC9) ( Supplementary Fig. 1c-e ).
We then examined whether SERCA2a is indeed SUMOylated in human hearts. The SERCA2a band was present along with other slowly migrating SERCA2a bands (Fig. 1a, top panel) , which represent the SUMOylated protein. The level of SUMOylated SERCA2a was significantly reduced in failing hearts compared to normal hearts. SUMOylation of SERCA2a was specific for SUMO1 (but not for SUMO2 or 3) ( Supplementary Fig. 1f ). Along with the reduction in SERCA2a, which is consistent with previous reports, the level of SUMO1 was also significantly reduced in failing hearts. However, the levels of UBC9 and SENP1, critical SUMOylating and de-SUMOylating enzymes, were unaltered in failing hearts (Fig. 1a, bottom panel) . These data indicate that the reduction in SERCA2a SUMOylation might be primarily due to the reduced level of SUMO1 and not to alterations in the level or activity of SUMOylating or de-SUMOylating factors. In additional experiments, we observed that the levels of both SUMO1 and SERCA2a were significantly reduced in a murine model of heart failure induced by pressure overload (Fig. 1b) , and in a porcine model of heart failure induced by volume overload (Fig. 1c ).
To characterize the potential role of SUMO1 during heart failure, we restored SUMO1 expression in a murine model of transverse aortic constriction (TAC)-induced heart failure. We delivered cardiotropic recombinant adeno-associated viruses, serotype 9 (rAAV9) when mice developed heart failure ( Fig. 1d ). Gene transfer of rAAV9-SUMO1 resulted in a dose-dependent increase in SUMO1 in the myocardium one month after gene transfer ( Supplementary Fig. 2 ). After induction of heart failure and before gene delivery (two months after TAC), cardiac function was markedly decreased in the mice. The TAC mice received tail-vein injection of either rAAV9-GFP (encoding green fluorescent protein, used as a negative control), rAAV9-SERCA2a (positive control) or rAAV9-SUMO1, and were followed for two more months. Cardiac function assessment by echocardiography revealed substantial improvements after rAAV9-SUMO1 gene delivery (at a total of four months after TAC), despite constant pressure overload, compared with severe deterioration in the rAAV9-GFP control (Fig. 1e, f and Supplementary Table 1 ). The mice injected with rAAV9-SUMO1 recovered cardiac function to the same degree as the mice injected with rAAV9-SERCA2a. Furthermore, haemodynamic analyses showed substantially improved left-ventricular function in the SUMO1-treated mice, and stabilization of the ratio of heart-weight to body-weight ( Supplementary Fig. 3 and Supplementary Table 2 ). The survival rate in the rAAV9-SUMO1-injected mice was also significantly extended compared with rAAV9-GFP-injected mice with heart failure (Fig. 1g ). Consistent with the improvement in cardiac performance in rAAV9-SUMO1-injected mice, protein levels of SERCA2a were significantly increased in rAAV9-SUMO1-injected mice compared with rAAV9-GFP-injected animals, indicating that SUMO1 restoration maintained SERCA2a levels during heart failure ( Fig. 1h ). Thus, we provide the first evidence, to our knowledge, that cardiac restoration of SUMO1 by rAAV9-mediated gene transfer enables long-term improvement of cardiac function. These findings provide further evidence that manipulating PTMs of SERCA2a may result in a functional benefit. SUMOylation usually occurs in a highly conserved recognition motif 8 . We found two putative SUMO conjugation sites in human SERCA2a, lysines 480 and 585. These residues are perfectly conserved in mouse, rat, pig and human SERCA2a ( Supplementary Fig. 4 ). We generated three SERCA2a variants with mutations in these lysines. Whereas K480R and K585R were SUMOylated at levels indistinguishable from wild-type SERCA2a, the K480R/K585R mutant was completely un-SUMOylated ( Fig. 2a ). Because the SUMOylated lysine residues, K480 and K585, reside in the nucleotide-binding domain that binds ATP, we predicted that SUMOylation might affect the ATPase activity of SERCA2a. As expected, the K480R/K585R mutant showed a significantly decreased ATPase activity compared to the wild type. SUMO1 co-expression significantly increased the ATPase activity of the wild type but did not affect the ATPase activity of K480R/K585R ( Fig. 2b ). We further tested whether SUMOylation affects the ATP-binding affinity of SERCA2a. Co-expression of SUMO1 markedly increased the ATP-binding affinity of the wild type. By contrast, K480R/K585R had considerably less ATP-binding affinity, which was not affected by SUMO1 co-expression ( Fig. 2c ). These data indicate that SUMOylation increases the ATPase activity of SERCA2a at least partially by enhancing its ATP-binding affinity.
Because both SERCA2a and SUMO1 levels were reduced in heart failure, we studied whether SUMOylation affects SERCA2a stability. The estimated half-life of the wild type was 4.9 days, which increased to 5.9 days when SUMO1 was co-expressed. The estimated half-life of the K480R/K585R mutant was significantly reduced compared to wild type (Fig. 2d ). In endoplasmic-reticulum-associated protein degradation, misfolded proteins are usually degraded by 26S proteasomes after polyubiquitination 9 . To determine whether the instability of the K480R/K585R mutant involves ubiquitin-dependent degradation, we performed ubiquitination assays of SERCA2a in HEK-293 cells. SUMO1 overexpression decreased levels of polyubiquitin-conjugated wild-type SERCA2a, whereas it did not alter polyubiquitination of the K480R/K585R mutant ( Supplementary Fig. 5 ). These data support our hypothesis that SUMOylation may compete with ubiquitination on SERCA2a, and indicate that SUMOylation increases the stability of SERCA2a by preventing 26S-proteasomal degradation of SERCA2a.
To examine the physiological function of SUMO1, we isolated cardiomyocytes from adult mice after TAC-induced heart failure or sham operation, and then infected the cells with adenovirus expressing either b-galactosidase (Ad-b-gal) or SUMO1 (Ad-SUMO1). When infected with Ad-SUMO1, cardiomyocytes from sham-operated mice showed significantly enhanced contractility compared to Ad-b-galinfected cardiomyocytes. A more prominent enhancement in contractility was observed when failing cardiomyocytes were infected with Ad-SUMO1. Ad-SUMO1-infected cardiomyocytes showed increased Ca 21 amplitude and faster Ca 21 decay compared to the Ad-b-gal-infected controls. The overall inotropic effect of SUMO1 overexpression was comparable to that induced by SERCA2a overexpression ( Fig. 3a) . It is possible that SUMO1 overexpression . TAC rAAV9-GFP, n 5 10; TAC rAAV9-SUMO1, n 5 14; TAC rAAV9-SERCA2a, n 5 12. g, Survival of animals after rAAV9-mediated SUMO1 restoration. The Kaplan-Meier method was used to analyse animal lifespan after infection with different viruses. rAAV9-GFP, n 5 12; rAAV9-SUMO1 or rAAV9-SERCA2a (5 3 10 10 vg mouse 21 ), n 5 24 in each group. Of 50 TAC-operated animals, 34 mice survived and were further divided into groups that received rAAV9-GFP (n 5 9), rAAV9-SUMO1 (n 5 13) or rAAV9-SERCA2a (n 5 12). h, Immunoblot results from a representative experiment and protein quantification (n 5 5 per group). All data represent the mean 6 s.d. *, P , 0.05 versus the respective control, as determined by Student's t-test.
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enhanced cardiomyocyte contractility at least partly by increasing the enzymatic activity and stability of SERCA2a.
Given our positive in vitro and gene-delivery results, we then proceeded to define the physiological consequences of SUMO1 overexpression in vivo. We generated cardiac-specific, Cre/loxP-conditional Sumo1-transgenic mice ( Supplementary Fig. 6a, b) . Along with increased SUMO1 levels, the levels of both SERCA2a itself and its SUMOylation were significantly induced by tamoxifen administration ( Supplementary Fig. 6c, d ). No cardiac dysfunction was apparent in these transgenic animals ( Supplementary Table 3 ). Wild-type and transgenic mice were subjected to TAC operations and heart failure developed in two months, characterized by a decrease of less than 50% in fractional shortening. One month after tamoxifen was administered (three months in total after TAC), cardiac function was examined. At this point, wild-type mice showed severe failing phenotypes with left ventricular dilation and a low ejection fraction. However, tamoxifeninduced overexpression of SUMO1 markedly reversed these failing phenotypes, resulting in less left ventricular dilation and improved fractional shortening and ejection fraction (Fig. 3b , c and Supplementary Table 4 ). Haemodynamic analyses also showed improved left ventricular function in the transgenic mice, along with stabilization of heart-weight to body-weight ratio ( Supplementary Fig. 7 and Supplementary Table 5 ). The recovery from cardiac dysfunction induced by SUMO1 overexpression was also manifested by the increased survival rate of transgenic animals under prolonged pressure overload ( Fig. 3d ). All transgenic animals survived 100 days after tamoxifen administration, whereas only seven out of fifteen wild-type animals survived at this time point. These findings are consistent with the results from the rAAV9 gene-delivery study.
Next, we monitored the expression levels of key regulatory proteins involved in Ca 21 homeostasis. After TAC, a notable reduction in the level of SERCA2a was observed, and levels of sodium/calcium exchanger 1 (SLC8A1, also known as NCX1) increased compared to sham-operated controls (Fig. 3e) . A decrease in SERCA2a function is coupled with an increase in NCX1 function in failing hearts 10 . The TAC-induced changes in the levels of SERCA2a and NCX1 did not occur in transgenic animals.
In wild-type animals, TAC resulted in a significant reduction of SERCA2a ATPase activity, but this was significantly lessened in the transgenic animals ( Fig. 3f ). Taken together, these data indicate that SUMO1 overexpression ameliorates cardiac dysfunction induced by pressure overload.
To evaluate the effects of downregulation of SUMO1 in hearts, we generated rAAV9 viruses that express SUMO1-directed shRNA (rAAV9-shSumo1), or a scrambled sequence (rAAV9-SC). We confirmed the efficiency and specificity of the shSumo1 in mice ( Supplementary Fig. 8a, b ). Six weeks after tail-vein injection of viruses, cardiac function was evaluated. Hearts from rAAV9-shSumo1injected mice showed left ventricular dilation and functional deterioration compared to hearts from rAAV9-SC-injected mice (Fig. 4a, b and Supplementary Tables 6 and 7 ). Injection of an increased dose of rAAV9-shSumo1 resulted in more severe cardiac dysfunction ( Supplementary Fig. 8c, d) . Cardiac dysfunction induced by rAAV9-shSumo1 manifested as sudden death of the mice. All mice receiving 1 3 10 11 viral genomes (vg) of rAAV9-shSumo1 died within 3 weeks. The death rates of mice that received 3 3 10 10 vg and 5 3 10 10 vg of rAAV9-shSumo1 were slightly higher than the rates in control mice that received rAAV9-SC (none of these control mice died) ( Fig. 4c ). SERCA2a protein levels were decreased by approximately 40% in rAAV9-shSumo1-injected hearts, and NCX1 levels were slightly elevated, although this was not statistically significant. As expected, SUMOylation of SERCA2a was also notably blunted ( Fig. 4d and Supplementary Fig. 8e ). These results support the premise that SUMO1 is important for the stability and function of SERCA2a. Downregulation of SUMO1 also significantly suppressed the ATPase activity of SERCA2a (Fig. 4e ), and this was further impaired when a higher dose of rAAV9-shSumo1 was injected ( Supplementary Fig. 8f ). These data show that SUMO1 is an essential regulator of SERCA2a function in the heart.
We next tested the SUMOylation status of some important cardiac transcriptional factors such as GATA binding protein 4 (GATA4) 11 and serum response factor (SRF) 12 . These factors are involved in cardiac pathogenesis and have been reported by other groups to be regulated by SUMOylation 11, 12 . The SUMOylation status and protein expression level of GATA4 were not altered by SUMO1 gene delivery, whereas SUMOylation of SRF was increased ( Supplementary Fig. 9 ). Increased SRF SUMOylation may contribute to the activation of certain genes, such as SERCA2a and genes encoding contractile proteins, during heart failure 13 . Several other transcriptional factors, such as SP1 and SP3, and calcium-regulatory signalling pathways, are associated with SERCA2a gene expression 14, 15 . Notably, the cleaved form of SRF was detected in failing hearts and this was decreased by SUMO1 and SERCA2a gene delivery. Recent studies have shown that caspase-3-mediated SRF cleavage occurs in heart failure 16 and SUMO1 overexpression blocks cell-death signalling induced by both tumour necrosis factor and FAS 17 . Our findings and other recent studies indicate that SUMO1 restoration increases levels of SUMOylated SRF and may alter apoptotic signalling in heart failure.
To determine the critical link between SUMO1 and SERCA2a in the setting of cardiac dysfunction, we knocked down SERCA2a using a lentiviral system carrying a shRNA directed towards Serca2a (shSerca2a). In isolated cardiomyocytes from rat and mouse, shSerca2a markedly and Myc-tagged UBC9 and wild-type or mutant SERCA2a. SUMOylated forms of SERCA2a were detected by immunoblot (IB) analysis using anti-SERCA2a antibody. IP, immunoprecipitation. b, Ca 21 -dependent ATPase activity of wild-type SERCA2a and the K480R/K585R mutant in the presence and absence of additional SUMO1. The data represent three independent experiments, each performed in duplicate. c, ATP binding capacity of wild-type and K480R/ K585R SERCA2a. Lysates from HEK-293 cells transfected with the indicated plasmids were affinity-precipitated with ATP-sepharose and subsequently subjected to immunoblot analysis with an anti-SERCA2a antibody. d, Effects of SUMO1 overexpression on the stability of wild-type and K480R/K585R SERCA2a mutant protein in HEK-293 cells. HEK-293 cells were transfected with wild-type or K480R/K585R SERCA2a expression plasmids, together with empty or SUMO1-expression plasmids. Cells were treated with cycloheximide 48 h after transfection to inhibit protein synthesis. Immunoblot analysis was performed with the indicated antibodies at different time points. Quantification data represent the ratio relative to day 0 (n 5 3). All data represent the mean 6 s.d. *, P , 0.05; **, P , 0.001 versus the respective control, as determined using Student's t-test.
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decreased contractile parameters and these were not improved by overexpression of SUMO1 ( Supplementary Figs 10a, b and 11a ). In vivo, rat ventricular function was significantly decreased after gene transfer of shSerca2a but no improvements were observed after co-infection with Ad-Sumo1 ( Supplementary Fig. 10c-f and Supplementary Table 8 ). In mice, antecedent overexpression of SUMO1 did not rescue ventricular function after lentiviral gene transfer of shSerca2a ( Supplementary  Fig. 11b-e and Supplementary Table 9 ). Taken together, these four experiments show that SERCA2a is critical in modulating SUMO1's beneficial effects in the setting of heart failure. However we cannot exclude that knockdown of SERCA2a may have effects on other proteins that would not allow SUMO1 to rescue contractile function.
We have showed that SERCA2a is SUMOylated at two lysine residues. We found that the levels of both SERCA2a itself and SERCA2a SUMOylation were significantly reduced in failing hearts. We have provided compelling evidence that the reduction of SERCA2a SUMOylation is a direct result of reduced SUMO1 levels in failing hearts. This reduction in SUMOylation correlated with reduced ATPase activity and decreased SERCA2a stability. Moreover, restoration of SUMO1 reversed contractile dysfunction in failing hearts. Our findings are summarized in Fig. 4f .
It is possible that SUMOylation may induce a conformational change 18 in SERCA2a or may provide an additional interface for ATP binding, leading to increased ATPase activity. It is also possible that SUMOylation may reciprocally and competitively affect other PTMs of SERCA2a and, in particular, may alter acetylation 19 . Notably, acetylation of SERCA2a was recently identified in a largescale analysis of the human acetylome in cancer cell lines 20 . We also found that SERCA2a is indeed acetylated and that this acetylation is more prominent in failing hearts and can be reversed by SIRT1 deacetylase (Kho et al., unpublished data). Further elucidation of the reciprocal or competitive relationship between SUMOylation and acetylation of SERCA2a is currently underway. There are precedents for this type of SUMOylation-mediated inhibition of protein degradation. For example, SUMOylation of axin, a negative regulator of Wnt signalling, prevents ubiquitination and thus induces a prolonged axin half-life 21 . Similarly, SUMOylation of the RNA helicases p68 and p72 increases their stability by reducing ubiquitin-proteasome-mediated protein degradation 22 . Detailed biochemical analyses are underway to identify the ubiquitination sites in SERCA2a.
Our data show that the amount of SUMO1 is reduced in failing hearts from various species, indicating that the level of cellular SUMO1 must be precisely maintained and controlled for proper cardiomyocyte function. Our finding that restoration of SUMO1 reversed TAC-induced heart failure indicates that a reduction in SUMO1 levels is a direct cause of contractile dysfunction. Our study was based on strong background data that has clearly established impaired SERCA2a as a key molecular abnormality in heart failure. The therapeutic effects of SUMO1, with near-complete recovery of contractile function, are notable, considering that expression of only a single gene is altered. In contrast to the reduction of SUMO1 levels in failing hearts, the levels of the SUMOylating and de-SUMOylating enzymes UBC9 and SENP1 were unaltered, and did not change when shSUMO1 was administered or when SUMO1 levels were restored (data not shown). Therefore, the specificity and capacity of SUMOylation itself is unlikely to be altered in failing hearts. Instead, the supply of SUMO1 itself seems to have the largest impact on SUMOylation. In this regard, it is notable that depletion of cellular ubiquitin is sufficient to cause neuronal dysfunction and death 23 . 
RESEARCH LETTER
In this study we demonstrate a novel regulatory mechanism whereby SUMOylation affects SERCA2a activity and the overall contractile properties of the heart. This highlights the importance of posttranslational mechanisms in experimental and human heart failure. In addition, the beneficial effects of SUMO1 on cardiac contractility and survival indicate that targeting SUMO1 may provide a novel therapeutic strategy for the treatment of heart failure.
METHODS SUMMARY
Animals. All mice and rats were housed and treated in accordance with guidelines from the NIH and institutional animal care and use committees, and the protocols used were approved by the Mount Sinai School of Medicine animal care and use committee. Human heart samples. Left ventricular samples were obtained from explanted human hearts obtained at the time of cardiac transplantation. Non-failing hearts (which were used as controls) were obtained from donors who died from neurological diseases or motor-vehicle accidents, and who had normal cardiac function by echocardiography. The five donors, three males and two females, had a median age of 62. The heart-failure patients, three males and two females, had a median age of 60 and their average ejection fraction was 20 6 3%. Fig. 1f , for rAAV9-shSC or rAAV9-shSumo1-injected mice (5 3 10 10 vg mouse 21 , n 5 14 per group). c, Survival of animals after rAAV9-mediated cardiac knockdown of SUMO1. Kaplan-Meier curves are shown for different doses of rAAV9-shSumo1 (n 5 14 per group) or rAAV9-shSC (5 3 10 10 vg mouse 21 , n 5 24). Solid line represents rAAV9-shSC-injected animals and dotted lines represent rAAV9-shSUMO1-injected animals. d, Representative immunoblot analysis for the indicated cardiac proteins in samples collected 6 weeks after tail-vein injection of rAAV9-shSC (5 3 10 10 vg mouse 21 , n 5 4) or rAAV9-shSumo1 (5 3 10 10 vg mouse 21 , n 5 7) (left panel). Quantification of GAPDH-corrected immunoblot signals (right panel). e, Ca 21 -dependence of ATPase activity of SERCA2a. ATPase activity was examined in preparations from shSC-injected and shSumo1injected hearts (5 3 10 10 vg mouse 21 , n 5 3 per group). All data represent mean 6 s.d. *, P , 0.05; **, P , 0.001 versus the respective control, as determined using Student's t-test. f, A working model for the regulation of SERCA2a function by SUMOylation. Under basal conditions, SUMOylation enhances the stability of SERCA2a and its Ca 21 pump function to regulate cardiac contractility. However, increased levels of unSUMOylated SERCA2a due to low SUMO1 protein pools trigger impaired SERCA2a activity and induce cardiac dysfunction under pathophysiological conditions. LETTER RESEARCH chromatography (Sigma). Finally, viruses were concentrated and formulated into lactated Ringer's solution (Baxter Healthcare Corporation) using Vivaspin 20 centrifugal concentrators 50K MWCO (Vivascience Inc.), and stored at -80 uC. Lentivirus. The lentiviral plasmids encoding shRNAs for Serca2a were previously described by us 28 . The Serca2a shRNA construct is the following sequence; the underlined segment indicates the loop: 59-GATCCGACTTACTAGTTAGAA TTTGGCTAAGAGCAAATTCTAACTAGTAAGTCTTTTTTGGAATTAAT-39. We used third-generation lentiviral systems to generate the vectors 29 . Transverse aortic constriction. Mice underwent TAC using a supraclavicular construction model as previously described 26 . TAC or sham surgery was performed in 8-week-old male mice (body weight 18-22 g). Mice were anesthetized with intraperitoneal ketamine and placed on a ventilator. A longitudinal cut of 2-3 mm was made in the proximal portion of the sternum, allowing visualization of the aortic arch. The transverse aortic arch was ligated between the innominate and left common carotid arteries with an overlying 27-gauge needle. The needle was immediately removed leaving a discrete region of constriction. The sham group underwent a similar procedure without ligation. Gene transfer in vivo. Adult Sprague-Dawley rats (body weight 240-260 g) underwent gene transfer via aortic cross-clamping as previously described 30 . After dissection of the aorta and pulmonary artery, lentiviral shSerca2a with or without adenoviral SUMO1 were injected into the left ventricular cavity through a 22G catheter while the aorta and pulmonary artery were cross-clamped for 50 s. In sham-operated animals, normal saline was injected into the left ventricular cavity while the aorta and pulmonary artery were cross-clamped for 50 s. After crossclamping was released, the chest was closed. Echocardiography. Transthoracic echocardiography was performed using a Vivid 7000 (GE Healthcare) equipped with a H13L transducer (14 MHz). Twodimensional and M-mode images were obtained in the short-axis view. The heart rate, left ventricular end-diastolic internal diameter and left ventricular end-systolic internal diameter were measured in at least three repeated cardiac cycles. The ejection fraction and fractional shortening were then calculated. Haemodynamics. Haemodynamic measurements are performed using a 1.2 Fr pressure-volume conductance catheter (Scisense). Pressure-volume loop analysis was performed as previously described 31 . Mice were injected intraperitoneally with urethane (1 g kg 21 ), etomidate (10 mg kg 21 ) and morphine (1 mg kg 21 ) and mechanically ventilated with 7 ml g 21 stroke volume at 125 respirations min 21 . The chest was opened to expose the heart for an apical stab approach. To determine absolute ventricular volumes via admittance technology, myocardial and blood conductance were obtained before pressure-volume catheter placement in the left ventricle 32 . The inferior vena cava was transiently occluded to reduce ventricular pre-load to obtain load-independent pressure-volume relationships. Haemodynamic measurements were acquired and analysed using IOX software (EMKAtech). Histological analysis. Hearts were prepared in Tissue-Tek OCT compound (Sakura Finetechnical) and sectioned into 6-mm slices (Microm HM560 Cryo-star, Thermo Scientific). The sections were stained with haematoxylin and eosin. Statistical analysis. Statistical analyses were performed using Student's t-test. Significant differences are indicated *, P , 0.05 or **, P , 0.001. Data in the figures represent mean 6 s.d.
